The suspected NAFLD group exhibited a significantly higher height (P < 0.001), BMI-SDS (P < 0.001), SBP-SDS (P < 0.001), DBP-SDS (P < 0.001), WC (P < 0.001), total cholesterol level (P < 0.001), TG level (P < 0.001), AST level (P < 0.001), ALT level (P < 0.001) and fasting glucose level (P = 0.039) than the healthy control group. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.